Cervical Cancer
Landoni Trial: Radical Surgery versus Radiotherapy for Stage Ib-IIa Cervical Cancer
There is no clear treatment of choice for early-stage cervical carcinoma in terms of overall or disease-free survival. Treatment should be tailored to individual patient factors such as menopausal status, age, medical conditions, histological type, and cervical diameter to achieve the best outcomes
Early Stage Cervical Cancer
ConCerv: Conservative Surgery in Early-Stage Cervical Cancer
Conservative surgery is feasible for select patients with early-stage, low-risk cervical cancer
SENTIREC: SLND in Cervical Cancer Study from Denmark
SENTICOL 2: Quality of Life After Sentinel Lymph Node Dissection in Cervical Cancer
SENTICOL 1: Sentinel LND in Cervical Cancer
CheckMate 358: Nivolumab with or without Ipilimumab in Recurrent/Metastatic Cervical Cancer
Nivolumab alone or in combination with ipilimumab shows promise in recurrent or metastatic cervical cancer, with significant objective response rates and manageable safety profiles.
KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
Pembrolizumab combined with chemoradiotherapy and then continued post-chemoradiotherapy demonstrates significant improvements in progression-free survival and OS compared to chemoradiotherapy alone
CALLA: Durvalumab versus Placebo with Chemoradiotherapy for Locally Advanced Cervical Cancer
Durvalumab concurrent with chemoradiotherapy was well tolerated but did not significantly improve progression-free survival compared to placebo in a biomarker-unselected all-comers population for locally advanced cervical cancer